|Table of Contents|

Efficacy of gefitinib,erlotinib and icotinib in advanced non-small cell lung cancer(NSCLC) with EGFR mutation

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 02
Page:
216-219
Research Field:
Publishing date:

Info

Title:
Efficacy of gefitinib,erlotinib and icotinib in advanced non-small cell lung cancer(NSCLC) with EGFR mutation
Author(s):
Cong Rinan; Gu Fang; Wang Bing
Weihai Municipal Hospital,Shandong Weihai 264200,China.
Keywords:
advanced non-small cell lung cancer; gefitinib; erlotinib; icotinib; EGFR gene
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2018.02.015
Abstract:
Objective:To compare the efficacy of the gefitinib,erlotinib and icotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.Methods：Clinical data about 76 patients with advanced non-small cell lung cancer in our hospital from May 2013 to December 2014 were retrospectively analyzed.They were randomly divided into gefitinib group,erlotinib group and icotinib group to evaluate the efficacy and safety.Results:There were no significant differences in the objective response rate and disease control rate of the three groups.The PFS of the three groups was 9.5 months,10 months and 9.5 months,respectively.The efficacy of the three drugs was similar.Conclusion：There is significant differences of gefitinib,erlotinib and icotinib in the patients with advanced EGFR mutation-positive NSCLC.But in patients with 19 exon deletion mutant,there is more advantage for erlotinib.

References:

[1]Shi YK,Sun Y,Ding CM,et al.China experts consensus on icotinib for non-small cell lung cancer treatment(2015 version)［J］.Chin J Lung Cancer,2015,18(7)：397-400.［石远凯，孙燕，丁翠敏，等.中国埃克替尼治疗非小细胞肺癌专家共识（2015版）［J］.中国肺癌杂志,2015，18（7）：397-400.］
[2]Fukuoka M,Wu Y,Thongprasert S,et al.Biomarker analyses and final overall survival results from a phase Ⅲ,randomized,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia（IPASS)［J］.J Clin Oncol,2011,29(21):2866-2874.
[3]Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer（OPTIMAL,CTONG-0802）:A multicentre,open-label,randomised,phase 3 study［J］.Lancet Oncol,2011,12(8):735-742.
[4]Gandara DR,Gumerlock PH.Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy:Case closed or is the jury still out［J］.J Clin Oncol,2005,23(25):5856-5858.
[5]Li XL,Tang XL,Li YP,et al.Efficacy and safety of EGFR-TKIs versus chemotherapy as the first line treatment for patients with advanced non-small cell lung cancer:A systematic review［J］.Chinese Journal of Evidence-Based Medicine,2016,16(02):191-199.［李向莲,唐雪莉,李幼平,等.EGFR-TKI与化疗比较一线治疗晚期非小细胞肺癌有效性和安全性的系统评价［J］.中国循证医学杂志,2016,16(02):191-199.］
[6]Kawaguchi T,Ando M,Asami K,et al.Randomized phase Ⅳ trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer:Docetaxel and erlotinib lung cancer trial（DELTA)［J］.J Clin Oncol,2014,32(18):1902-1908.
[7]Roengvoraphoj M,Tsongalis GJ,Dragnev KH,et al.Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer:Focus on epidermal growth factor receptor mutation testing and mutation-positive patients［J］.Cancer Treatment Rev,2013,39(8):839-850.
[8]Janne PA,Engelman JA,Johnson BE.Epidermal growth factorreceptor mutations in non-small-cell lung cancer:Implications for treatment and tumor biology［J］.J Clin Oncol,2005,23(14):3227-3234.
[9]Xie YL,Lang JZ,Su N.Gefitinib versus erlotinib as first-linetreatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer［J］.J South Med Univ,2015,35(3):446-449.［谢亚琳，梁继珍，苏宁.吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较［J］.南方医科大学学报,2015,35(3):446-449.］
[10]Zhou F，Zhou CC.Targeted therapies forpatients with advanced NSCLC harboring wild-type EGFR：What's new and what's enough［J］.Chin J Cancer,2015,34(7):31.［周斐,周彩存.野生型EGFR的晚期非小细胞肺癌患者的靶向治疗：有什么新的和充足的治疗［J］.癌症（英文版）,2015,34(7):31.］
[11]Jiang XW,Wang WX,Zhang YP.Clinical analysis of icotinib on beneficiary of advanced non-small cancer with EGFR common mutation［J］.Chinese Journal of Lung Cancer,2016,19(04):200-206.［蒋小雯,王文娴,张沂平.埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析［J］.中国肺癌杂志,2016,19(04):200-206.］
[12]Shi Y,Zhang L,Liu X,et al.Icotinib versus gefitinib in previousl treated advanced non-small-cell lung cancer(ICOGEN):A randomised,double-blind phase 3 non-inferioritytrial［J］.Lancet Oncol,2013,14(10):953-961.
[13]Kim ST,Lee J,Kim JH,et al.Comparison of gefitinib versus erlotinib in patients with non small cell lung cancer who failed previous chemotherapy［J］.Cancer,2010,116(12):3025-3033.
[14]Ahn J,Kim S,Ahn M,et al.Randomized phaseⅡstudy of gefitinib versus erlotinib in patients with advanced non-samll cell lung cancer who failed previous chemotherapy［J］.Lung Cancer,2012,75(1):82-88.
[15]Cao FF,Zhang LL,Wang S,et al.Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer:A Meta-analysis［J］.Chin J Lung Cancer,2015,18(03):146-154.［曹飞飞,张琳琳,王双,等.EGFR-TKIs与化疗比较一线治疗非小细胞肺癌疗效的Meta分析［J］.中国肺癌杂志,2015,18(03):146-154.］

Memo

Memo:
-
Last Update: 2017-11-30